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OBJECTIVES: Estimate the clinical and economic impact to U.S. hospitals of air leaks 
during post-operative pulmonary surgery using the Medicare Provider Analysis and 
Review (MEDPAR) data set. METHODS: The 2008 The Medicare Provider Analysis 
and Review (MEDPAR) data set contains records for 100% of Medicare beneﬁ ciaries 
who use hospital inpatient services. For all stays with pulmonary surgery, length of 
stay (LOS), total charges, and in-hospital mortality rates were compared between those 
stays including an air leak vs. those stays without an air leak. Unadjusted results were 
calculated using descriptive statistics (mean, median, frequencies, etc.) Adjusted results 
were calculated using multivariate regression analysis while controlling for age and 
gender. RESULTS: There were a total of 41,348 hospital inpatient stays with pulmo-
nary surgery in the 2008 MEDPAR data set, of these 8,774 (21.2%) included air leak 
and 32,574 (78.8%) of which did not. In the MEDPAR data set patients with pulmo-
nary surgery stays including air leak had a similar age distribution to patients without 
air leak, had a longer LOS on average (10.7 days vs. 7.2 days; P < .0001), had more 
total charges ($78,830 vs. $63,528; P < .0001) and were nearly equally likely to die 
during their stay (14.8% vs. 13.94%; p = 0.057). After adjusting for differences in 
age and gender between the two groups, the incremental LOS and total charges due 
to the presence of air leak is 3.4 days and $14,532 respectively. The total additional 
economic impact of having an air leak after pulmonary surgery, estimated by applying 
patient level adjusted charges to the incidence of air leak, is $127.5 million. CONCLU-
SIONS: The clinical and economic impact to U.S. hospitals of air leaks during or 
following major pulmonary surgery is signiﬁ cant. The reduction of these air leaks 
could save considerable hospital resources, payer dollars and patient lives.
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OBJECTIVES: Iatrogenic pneumothorax occurs when air or gas becomes present in 
the pleural cavity following medical treatment. Besides subjecting the patient to 
unnecessary health risks, iatrogenic pneumothorax leads to an increased amount of 
health care resources including observed through patient cost, length of stay, and 
inpatient mortality. This research aims to quantify the incremental effects of iatrogenic 
pneumothorax on these three outcomes. METHODS: Discharge records from Pre-
mier’s Perspective database of US inpatients who underwent inpatient pulmonary 
surgery and were discharged in 2007 were examined. The deﬁ nition of iatrogenic 
pneumothorax consistent with ICD-9-CM code 512.1 was used to classify patients. 
Chi-square tests were used to detect differences between iatrogenic pneumothorax 
patients and non-iatrogenic pneumothorax patients for three outcomes. Multivariable 
regression models were used to obtain more precise estimates of the incremental effects 
of iatrogenic pneumothorax on outcomes while controlling for comorbidities, demo-
graphic variables and the patient’s primary treatment. RESULTS: A total of 112,827 
patients were analyzed (8,482 with iatrogenic pneumothorax). Chi-square tests dem-
onstrated that patients with iatrogenic pneumothorax were older (P < 0.0001), had 
lower hospital costs (P < 0.0001), a shorter length of stay (P < 0.0001), and lower 
mortality rate (P < 0.0001). Log linear modeling demonstrated iatrogenic pneumotho-
rax increases patient costs by 10.49% (95%CI: 8.76%–12.23%). Negative binomial 
models showed iatrogenic pneumothorax increases patients length of stay by 8.01% 
(95% CI: 6.21%–9.82%), while no difference was found with respect to mortality. 
CONCLUSIONS: The incremental effects of iatrogenic pneumothorax are shown to 
signiﬁ cantly increase patient costs and length of stay but not inpatient mortality.
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OBJECTIVES: to assess social and economic burden of a Bronchial asthma and 
Chronic Obstructive Pulmonary Disease in Russian Federation. METHODS: “Cost 
of illness” analysis was performed. Available data on epidemiology of bronchial 
asthma and chronic obstructive pulmonary disease in the Russian Federation has been 
analyzed. Experts were questioned to describe the common practice of treating patients 
with bronchial asthma and chronic obstructive pulmonary disease. Direct costs, indi-
rect costs and intangible costs were calculated. RESULTS: According to the state 
registration data, in 2007 the number of patients with bronchial asthma was 1.3 
million and with chronic obstructive pulmonary disease— 2.4 million. The burden of 
bronchial asthma incorporates direct costs (c220.9 million), indirect costs (c67.4 
million) and intangible costs (c69.6 million). The burden of chronic obstructive pul-
monary disease is c210.6 million, c212 million, c207 million for direct costs, indirect 
costs and intangible costs respectively. Cost of BA and COPD is c987.8 million. 
CONCLUSIONS: According to the results of the analysis Bronchial asthma and 
Chronic Obstructive Pulmonary Disease proved to be an important medical and social 
problem in Russian Federation.
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OBJECTIVES: About two million people suffer from COPD in Poland. The aim of 
this study was to examine direct, mean costs of COPD in Poland under usual clinical 
practice form societal perspective. METHODS: It was an observational retrospective 
and prospective bottom-up-cost-of- illness study, based on a retrospective sample of 
patients presenting with COPD. Total medical resources consumption of a sample of 
COPD patients were collected in 2008 year trough physician—lung specialists. Direct 
costs of COPD were evaluated based on data from different populations of ﬁ ve clinical 
hospitals and eight ambulatory cares. Medical resource consumptions were catego-
rized by investigators as usual COPD follow up and number and severity of exacerba-
tions.Resources utilization and cost data are summarised as mean values per patient 
per year; 95% conﬁ dence intervals were derived using percentile bootstrapping. 
RESULTS: In patients studied, number of free –of- exacerbation days was 331, 1, 
mean number of outpatient exacerbation was 1.27, mean number of exacerbations 
requiring hospital was 0.24. Average total medical resource consumption of a COPD 
patient per year was c1006.1. Among this cost c605 was directly related to treatment 
of stable COPD (costs of drugs, additional exams, costs of medical visits, inﬂ uenza 
vaccination and home oxygen therapy), c105.3 to outpatient exacerbation, and c295.8 
to exacerbation treated in hospital. CONCLUSIONS: The burden of COPD itself 
appeared to be considerable magnitude from societal perspective in Poland. Overall, 
the main cost drivers were inpatient care and prescription medication.
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OBJECTIVES: We compared two alternative methods (recycled prediction and Oax-
aca-decomposition) to estimate medical costs attributable to obesity in US adults with 
asthma. METHODS: This study used the 2003–2007 Medical Expenditure Panel 
Survey to select asthma patients (18–64 years old), excluding patients with pregnancy, 
malignancy, kidney dialysis, immunodeﬁ ciency, or low body mass index (BMI < 18.5 
kg/m2). Obesity was deﬁ ned as BMI >= 30 kg/m2. Medication costs were estimated 
using a generalized linear model with a log-link function and gamma distribution. For 
the recycled predictions method, predicted treatment costs for obese patients were 
calculated assuming that obese patients were normal-weight, holding the distribution 
of covariates obtained from the entire asthma patient sample. With Oaxaca-decom-
position, average treatment costs for each group (obese vs. normal weight) were 
estimated. The differences in average costs between the two groups were then esti-
mated for two components: a) costs due to patient characteristics (endowments), and 
b) costs due to obese/normal-weight parameters (coefﬁ cient), considered as costs 
attributable to obesity. To compare the two methods, the difference in costs between 
obese and normal-weight patients was simulated, after matching for patient demo-
graphic and clinical characteristics,. All costs were converted to 2009 US dollars using 
price indices. RESULTS: The prevalence of obesity and normal-weight among 7340 
asthmatic patients was 32.5% vs. 35.1%, respectively. In the recycled prediction 
method, costs attributable to obesity were US$1798 (95%CI: US$1717–$1878). In 
the Oaxaca-decomposition, the difference in medical costs between two groups con-
sisted of US$1357 (95%CI: US$1252–$1462) due to endowments and US$1285 (95% 
CI: US$1229–$1341) due to coefﬁ cient components (i.e. costs attributable to obesity). 
The difference in costs from the simulation was US$1124 (US$1045–US$1203). CON-
CLUSIONS: Costs attributable to obesity obtained using Oaxaca-decomposition were 
similar to those of the simulation method, but the costs obtained using the recycled 
prediction method were higher than those of Oaxaca-decomposition and 
simulation.
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OBJECTIVES: We aimed to estimate the long-term (cost-)effectiveness of smoking 
cessation interventions for patients with chronic obstructive pulmonary disease 
(COPD). METHODS: A systematic review was performed for randomized controlled 
trials on smoking cessation interventions in COPD patients reporting the 12-month 
biochemical validated abstinence rates. The different interventions were grouped into 
four categories: usual care, minimal counseling, intensive counseling and intensive 
counseling plus pharmacotherapy. For each category the average 12-months continu-
